Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

In this study, a validated chromatographic method demonstrated the ability to simultaneously analyze gemcitabine and olaparib in pancreatic cancer tissues, supporting the advancement of pharmaceutical formulations combining these drugs, particularly for patients with BRCA mutations.